Pharmaceutical versions of GLP-1, such as semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound), were initially developed to treat type 2 diabetes but are now widely prescribed for weight loss and other health conditions
Diabetes 63 , 471482 (2014)
The contribution of psychiatric AEs in GLP-1 RAs is not prominent compared with the background frequency of the SOC level, but with the dramatic increase in the number of GLP-1 RAs used, psychiatric AEs remain a notable proportion of the overall AEs associated with GLP-1 RAs ( Table 1 )
Federal restrictions have historically prevented Medicare from covering weight-loss medications
These are summarized in Fig
When we talk about microdosing GLP-1, were referring to doses substantially lower than whats typically prescribed for weight loss